Ironwood Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: IRWDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
3.82-0.05 (-1.29%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ironwood Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Ironwood Pharmaceuticals generated $58.3 million of operating cash flow. That left free cash flow of $58.3 million, a free-cash-flow margin of 51.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Ironwood Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 51.29M | 40.77M | -2.28M | 40.08M | 23.60M | -37.39M | 2.26M | 3.65M | -860.00K | -4.16M | -1.75M | 13.95M |
| Net Income growth (YoY) | +117.34% | — | -200.89% | +999.29% | — | — | — | -73.86% | — | -109.10% | -103.57% | -72.28% |
| Depreciation & Amortization | 457.00K | 443.00K | 460.00K | 475.00K | 467.00K | 479.00K | 485.00K | 507.00K | 506.00K | 513.00K | 512.00K | 507.00K |
| Stock-Based Compensation | 3.24M | 3.65M | 3.82M | 3.61M | 4.52M | 5.29M | 4.57M | 8.33M | 8.57M | 8.38M | 8.70M | 7.91M |
| Change in Working Capital | -11.49M | -63.86M | 73.41M | -23.44M | -60.09M | 51.92M | -11.32M | -17.99M | 10.87M | 44.61M | -17.09M | 954.00K |
| Operating Cash Flow | 58.28M | 5.12M | 74.58M | 47.58M | -15.07M | 19.95M | 15.21M | 9.88M | 33.47M | 44.98M | 35.83M | 32.46M |
| Capital Expenditures | — | — | 1.00K | -2.00K | -2.00K | -31.00K | 0 | -16.00K | -58.00K | -68.00K | -211.00K | -49.00K |
| Investing Cash Flow | — | — | 1.00K | -2.00K | -2.00K | -31.00K | 0 | -16.00K | -58.00K | -68.00K | -4.19M | -22.63M |
| Financing Cash Flow | — | — | 122.00K | 0 | 88.00K | 6.00K | -14.89M | -27.16M | -49.37M | -15.55M | -50.90M | -74.99M |
| Net Change in Cash | -141.34M | 5.01M | 75.05M | 47.55M | -15.63M | 19.92M | 348.00K | -17.31M | -16.02M | 29.39M | -19.31M | -65.16M |
| Free Cash Flow | 58.28M | 5.12M | 74.58M | 47.58M | -15.07M | 19.92M | 15.21M | 9.87M | 33.41M | 44.92M | 35.62M | 32.41M |
This table shows 12 quarterly periods of Ironwood Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IRWD's reporting calendar. What is a cash flow statement?